| January 23, 2014 | ISSUE NUMBER 335 VOL 1 |
Outlook
Pharm Exec’s Annual Industry Outlook 2014
For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. As our annual industry outlook confirms, it’s time to be decisive — muddling through is so ‘yesterday’ ...Read more
Outlook
J.P. Morgan Conference: Pharma’s Agenda for 2014
Presenters at the 32nd annual J.P. Morgan Healthcare Conference this month talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Ben Comer reports ...Read more
AndaMEDS is a division of Anda Inc., a leading national distributor of pharmaceuticals
AndaMEDS offers a broad selection of vaccines, specialty injectables and medications administered in physicians' offices. Established in 1995, we service thousands of physician practices and create targeted marketing and customized distribution services for our manufacturer partners. www.andameds.com
Healthcare Reform
Obamacare: The Questions Pharma Will Be Asking in 2014
It’s expected that about 35 new FDA approved prescription drugs will arrive on the market in 2014. What are the chances that these new medications will be utilized by Obamacare health programs? Tom Norton considers these and other questions ...Read more
Regulatory
FDA Rolls Out Social Media Guidelines — Slowly
Pharma marketers have been clamoring for clear advice from FDA on how to accommodate established rules governing drug promotion to today’s world of internet communications and social messaging. Now, a guidance from the agency’s Office of Prescription Drug Promotion (OPDP) outlines agency preferences for how marketers should monitor and provide information of its online communications activities ...Read more
Innovation
The Moneyball Test
Successful innovation now has to align with key metrics of value — can an old baseball metaphor help guide the way? ...Read more
|
|
|
|
 //Advanced Cell Technology (Marlborough, MA) announced that Gary Rabin stepped down as Chief Executive Officer. The Board has appointed the Company’s CFO and Executive Vice President of Corporate Development, Edward Myles, as interim President while it initiates a search for a permanent CEO.//Keryx Biopharmaceuticals, Inc. (New York, NY) announced the appointment of Daniel W. Olmstead to the newly created position of Vice President, Payer Access.//The UK-headquartered Biotec Services International recruited Doug Basinger as part of a strategic plan to build its U.S. operation.//The Illinois Biotechnology Industry Organization (iBIO) announced the election of Andy Hull, Vice President of Global Alliance Management for Takeda, as Chairman of the iBIO Board of Directors. Linda Friedman, Senior Vice President and General Counsel at Astellas US LLC, also joined as Chairperson. iBIO also elected Joe Nolan, Chief Commercial Officer of Lundbeck, Inc., and Claudia Roth, President of Vetter Development Services USA, Inc., to the Board.// |
|
|
|
|
|
 |
|
|
|
| |
|
|
|
 |
|
 |
What in your opinion poses the biggest threat to the industry over the next five years?
|
|
|
|
